



EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action/Capital Increase

Marinomed Biotech AG: Publication of a report on the exclusion of subscription rights for a possible second cash capital increase of up to 154,053 shares

27-Nov-2024 / 12:49 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

Korneuburg, Austria, 27. November 2024 - As Marinomed Biotech AG (the "Company" or "Marinomed") announced in its ad hoc announcement dated 18 September 2024 regarding the first cash capital increase of 154,053 new shares (the "First Cash Capital Increase"), the Company is negotiating with investors regarding a possible second cash capital increase, which would be carried out in accordance with the authorisation to exclude the subscription rights of existing shareholders (the "Second Capital Increase"). Marinomed is currently continuing to discuss with several investors such a Second Capital Increase, although no agreements or board resolutions have yet been reached.

The Company's Management Board has resolved today to publish a report on the intended exclusion of subscription rights of existing shareholders for a possible cash capital increase of up to EUR 154,053 by issuing up to 154,053 new no-par value bearer shares against cash contribution (the "Report"). The Report on the exclusion of subscription rights is to be published as soon as possible on the electronic announcement and information platform of the Federal Government of Austria ("EVI").

With the publication of the Report, the Company's Management Board ensures that, in the event of a short-term financing requirement of the Company, the Company's Management Board is legally in a position to resolve on a new cash capital increase from the authorised capital 2024 in accordance with § 5 para (6) of the Company's Articles of Association (the "Authorised Capital 2024") at short notice with the approval of the Supervisory Board. The background to this is that a report on the planned exclusion of subscription rights must be published at least two weeks prior to the required Supervisory Board resolution. Against the background of the cash ratio to be deposited in accordance with the adopted restructuring plan, the Company is creating the prerequisite for being able to raise necessary equity at short notice and not having to wait for the two-week period to expire in this case.

The actual implementation of a possible Second Capital Increase remains dependent on the outcome of negotiations with investors, the conclusion of the respective transaction documents and the adoption of resolutions by the Company's Management Board and Supervisory Board. In addition, the restructuring proceedings (still needed for a Second Capital Increase) require the approval by the restructuring administrator.

+++ End of ad-hoc announcement +++

End of Inside Information

27-Nov-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com

Language:	English
Company:	Marinomed Biotech AG Hovengasse 25 2100 Korneuburg Austria
Phone:	+43 2262 90300
E-mail:	office@marinomed.com
Internet:	www.marinomed.com
ISIN:	ATMARINOMED6
WKN:	A2N9MM
Listed:	Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market)
EQS News ID:	2039559

End of Announcement

EQS News Service